文献速递神经肿瘤脊柱脊髓外科

多分次脊柱立体定向放疗治疗脊柱转移瘤

Multi-fraction stereotactic body radiotherapy for spinal metastases.
PubMed 文献 · J Neurooncol · 2026-04-27

本研究基于2002至2024年前瞻性脊柱SBRT数据库分析146次治疗,评估多分次SBRT对体积大、压迫脊髓或既往接受过常规外照射的脊柱转移瘤的疗效与安全性。中位随访9个月,局部肿瘤控制率6、12、24个月分别为89%、84%、78%,疼痛改善或稳定在1、3、6个月分别为93%、89%、87%,中位总生存13个月,椎体压缩骨折粗发生率为9%。

要点

  • 多分次SBRT对大体肿瘤、脊髓压迫或既往放疗的脊柱转移瘤安全有效。
  • 溶骨性病变和跨越超过1个椎体节段与局部控制变差显著相关。
  • KPS≤80和放射抵抗性原发肿瘤组织学与总生存变差显著相关。

核心结论

  • 多分次脊柱SBRT对大的脊柱转移瘤安全有效,包括既往接受过常规外照射的肿瘤。

研究设计与样本

  • 分析2002至2024年前瞻性维护的脊柱SBRT数据库,共146次治疗,排除缺失基线影像或随访不足1个月者。
  • 最常见分割方案为24 Gy/2次、24 Gy/3次和30 Gy/5次,中位肿瘤体积40 cc(IQR:18–79)。
  • 108个肿瘤(74%)既往接受过常规外照射,109个肿瘤(75%)存在硬膜外肿瘤延伸。

主要发现

  • 中位随访9个月(IQR:2–17),18个肿瘤(12%)出现局部肿瘤进展,6、12、24个月局部肿瘤控制率分别为89%、84%、78%。
  • 溶骨性病变(HR:8.63,95%CI:1.11–67.3,p=0.040)和跨越超过1个椎体节段(HR:2.76,95%CI:1.02–7.46,p=0.046)与局部肿瘤控制变差显著相关。
  • SBRT后1、3、6个月疼痛改善或稳定的病例分别为93%、89%、87%。
  • 中位总生存13个月,KPS≤80(HR:0.41,95%CI:0.26–0.64,p<0.001)和放射抵抗性原发肿瘤组织学(HR:0.50,95%CI:0.31–0.80,p=0.004)与总生存变差相关。
  • 椎体压缩骨折粗发生率为9%。

临床怎么用

  • 对于体积大、压迫脊髓或既往接受过常规外照射的脊柱转移瘤,可考虑采用多分次脊柱SBRT。
  • 治疗前评估溶骨性病变和跨越超过1个椎体节段等局部控制不良因素。
  • 关注KPS≤80和放射抵抗性原发肿瘤组织学患者的生存预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Single-fraction stereotactic body radiotherapy (SBRT) has demonstrated efficacy in the management of spinal metastases. This study sought to investigate the role of multi-fraction spine SBRT in managing metastatic spinal tumors, particularly for tumors large in volume, compressing the spinal cord, or previously irradiated with conventional external beam radiotherapy (EBRT). METHODS: Overall, 146 treatments were analyzed from a prospectively maintained spine SBRT database from 2002 to 2024. Treatments were excluded for missing baseline imaging or less than 1 month of follow-up. The most prescribed fractionation schemes were 24 Gy/2 fractions, 24 Gy/3 fractions, and 30 Gy/5 fractions. The median tumor volume was 40 cc (IQR: 18–79). Tumors were previously irradiated with EBRT (108 tumors, 74%), and most had epidural tumor extension (109 tumors, 75%). RESULTS: The median follow-up was 9 months (IQR: 2–17). Eighteen (12%) tumors exhibited local tumor progression with local tumor control (LTC) rates of 89%, 84%, and 78% at 6-, 12-, and 24- months following SBRT. Lytic lesions (HR: 8.63, 95%CI: 1.11–67.3, p = 0.040) and tumors spanning > 1 vertebral level (HR: 2.76, 95%CI: 1.02–7.46, p = 0.046) were significantly associated with worsened LTC. Pain improvement or stability was noted for 93%, 89%, and 87% of treated cases at 1-, 3-, and 6-months post-SBRT. The median overall survival (OS) was 13 months with KPS ≤ 80 (HR: 0.41, 95%CI: 0.26–0.64, p < 0.001) and radioresistant primary tumor histology (HR: 0.50, 95%CI: 0.31–0.80, p = 0.004) being associated with worsened OS. The crude vertebral compression fracture development rate was 9%. CONCLUSION: Multi-fraction spine SBRT is safe and effective for large spinal metastatic tumors, including those previously irradiated with EBRT.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Taori S, Adida S, Rajan A, et al. Multi-fraction stereotactic body radiotherapy for spinal metastases. J Neurooncol. 2026. PMID: 42043597. doi:10.1007/s11060-026-05579-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。